News From Industry Sources
Kingfisher announces FDA clearance of breakthrough KFH Energy for chronic pain sufferers
March 31, 2008
The patented, high-tech medical device is intended to improve upon quality of life for sufferers of chronic pain associated with post-polio syndrome, fibromyalgia, multiple sclerosis, and chronic fatigue syndrome. The device utilizes a unique form of micro current electrotherapy called Bio-Electric Stimulation Therapy,which is designed to enhance the body's physiological processes. Story
Smiths medical receives FDA clearance for next generation CADD(R)-Solis Ambulatory Infusion System
March 23 2008
Smiths Medical announced that it has received clearance from the US Food and Drug Administration for its CADD(R)-Solis Ambulatory Infusion System, a clinically and technologically advanced next generation ambulatory infusion platform that enhances patient safety and personalized care for pain management patients. Story
Family of three Americans become pain free and improve their quality of life with stem cell treatment in Mexico
March 23 2008
Optimum Health Regeneration Center announced the successful treatment of an American family treated for pain management and impaired mobility. This New Mexico family, ranging in age from 52 to 78, all recorded significant improvements in reduced pain, increased physical mobility and in their quality of life after receiving treatment with umbilical cord stem cells and ozone therapy Story
FDA classifies Medtronic's physician communication related to inflammatory mass formation from intrathecal drug therapy
March 19, 2008
Medtronic, Inc. announced that the U.S. Food and Drug Administration has classified its communication to physicians related to inflammatory mass formation associated with intrathecal drug delivery as a Class I Recall. Story
Leading rheumatologists agree clinical remission a key goal in rheumatoid arthritis
March 17, 2008
In the first major rheumatoid arthritis trial to use clinical remission as a primary endpoint, over 50% of patients with less than two years of early active rheumatoid arthritis who received a combination of Enbrel (etanercept) and methotrexate achieved clinical remission. Story
Glenmark gets US nod for sale of arthritis drug
March 17, 2008
Glenmark Pharmaceuticals Inc. has started the shipping of its non-steroid and anti-inflammatory drug (Nabumetone) to the US following approval by the country's drug authorities. Story
|
